Epigral Limited
NSE: EPIGRAL · Specialty Chemicals
Snapshot
Unlock Epigral Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Epigral Limited is a specialty chemical manufacturer producing chlor-alkali products and derivatives, including CPVC resins, epichlorohydrin, and chloromethanes. The company serves a diverse range of industrial sectors such as construction, pharmaceuticals, agrochemicals, and electronics.
Business Model
The company generates revenue through the manufacturing and sale of chemical products and the trading of agrochemical goods. It leverages integrated production facilities to supply essential raw materials to various downstream industrial applications.
Growth Outlook
Growth is driven by the expansion of its specialty chemical portfolio and increasing demand from high-growth sectors like CPVC pipes, water treatment, and lithium processing. The company continues to focus on diversifying its product mix to capture higher-margin opportunities.
Key Risks
- Raw Material Price Volatility. Fluctuations in the prices of key feedstocks like salt and power can significantly impact manufacturing margins.
- Regulatory and Environmental Compliance. The chemical manufacturing sector faces stringent environmental regulations that may necessitate high capital expenditure for compliance.
- Cyclicality of Chlor-Alkali Industry. The company is exposed to the inherent cyclical nature of the global chlor-alkali market, which is sensitive to industrial demand cycles.
- Geopolitical and Trade Risks. As an exporter, the company is susceptible to changes in international trade policies and global economic conditions.
Start your research today
Unlock AI insights, financials, peers and live data on Epigral Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,626 Cr
TTM · consolidated
NET PROFIT
₹271 Cr
TTM · consolidated
EPS
₹62.82
TTM · consolidated
RETURN ON EQUITY
13.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
19.4x
Q1 FY27 · consolidated
EV/EBITDA
9.8x
Q1 FY27 · consolidated
EBITDA MARGIN
22.6%
TTM · consolidated
NET PROFIT MARGIN
14.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Epigral LimitedEPIGRAL | ₹5,262 Cr | 19.42 | 9.80 | 4.8% | 22.6% | 13.1% | 15.5% | -31.2% |
Neogen Chemicals LimitedNEOGEN | ₹5,854 Cr | 160.87 | 44.08 | 18.0% | 17.6% | 4.4% | 9.7% | +44.9% |
Yasho IndustriesYASHO | ₹4,985 Cr | 86.43 | 29.85 | 35.3% | 19.7% | 13.4% | 16.5% | +121.7% |
Laxmi Organic Industries LimitedLXCHEM | ₹4,769 Cr | 37.89 | 19.57 | 5.5% | 8.6% | 6.5% | 8.3% | -19.6% |
Vishnu Chemicals LimitedVISHNU | ₹4,726 Cr | 31.51 | 17.90 | 16.6% | 17.3% | 15.0% | 19.4% | +44.9% |
Foseco India LimitedFOSECOIND | ₹4,721 Cr | 55.20 | 36.89 | 12.2% | 20.4% | 11.2% | 15.4% | -2.6% |
As of Q1 FY27
Financials
Epigral Limited
NSE: EPIGRAL · Specialty Chemicals
Snapshot
Unlock Epigral Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Epigral Limited is a specialty chemical manufacturer producing chlor-alkali products and derivatives, including CPVC resins, epichlorohydrin, and chloromethanes. The company serves a diverse range of industrial sectors such as construction, pharmaceuticals, agrochemicals, and electronics.
Business Model
The company generates revenue through the manufacturing and sale of chemical products and the trading of agrochemical goods. It leverages integrated production facilities to supply essential raw materials to various downstream industrial applications.
Growth Outlook
Growth is driven by the expansion of its specialty chemical portfolio and increasing demand from high-growth sectors like CPVC pipes, water treatment, and lithium processing. The company continues to focus on diversifying its product mix to capture higher-margin opportunities.
Key Risks
- Raw Material Price Volatility. Fluctuations in the prices of key feedstocks like salt and power can significantly impact manufacturing margins.
- Regulatory and Environmental Compliance. The chemical manufacturing sector faces stringent environmental regulations that may necessitate high capital expenditure for compliance.
- Cyclicality of Chlor-Alkali Industry. The company is exposed to the inherent cyclical nature of the global chlor-alkali market, which is sensitive to industrial demand cycles.
- Geopolitical and Trade Risks. As an exporter, the company is susceptible to changes in international trade policies and global economic conditions.
Start your research today
Unlock AI insights, financials, peers and live data on Epigral Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,626 Cr
TTM · consolidated
NET PROFIT
₹271 Cr
TTM · consolidated
EPS
₹62.82
TTM · consolidated
RETURN ON EQUITY
13.1%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
19.4x
Q1 FY27 · consolidated
EV/EBITDA
9.8x
Q1 FY27 · consolidated
EBITDA MARGIN
22.6%
TTM · consolidated
NET PROFIT MARGIN
14.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Specialty Chemicals
As of Q1 FY27